BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 30723315)

  • 1. Variants in vincristine pharmacodynamic genes involved in neurotoxicity at induction phase in the therapy of pediatric acute lymphoblastic leukemia.
    Martin-Guerrero I; Gutierrez-Camino A; Echebarria-Barona A; Astigarraga I; Garcia de Andoin N; Navajas A; Garcia-Orad A
    Pharmacogenomics J; 2019 Dec; 19(6):564-569. PubMed ID: 30723315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia.
    Lopez-Lopez E; Gutierrez-Camino A; Astigarraga I; Navajas A; Echebarria-Barona A; Garcia-Miguel P; Garcia de Andoin N; Lobo C; Guerra-Merino I; Martin-Guerrero I; Garcia-Orad A
    Pharmacogenomics; 2016 May; 17(7):731-41. PubMed ID: 27180762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of association of the CEP72 rs924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population.
    Gutierrez-Camino A; Martin-Guerrero I; Lopez-Lopez E; Echebarria-Barona A; Zabalza I; Ruiz I; Guerra-Merino I; Garcia-Orad A
    Pharmacogenet Genomics; 2016 Feb; 26(2):100-2. PubMed ID: 26618658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia.
    Diouf B; Crews KR; Lew G; Pei D; Cheng C; Bao J; Zheng JJ; Yang W; Fan Y; Wheeler HE; Wing C; Delaney SM; Komatsu M; Paugh SW; McCorkle JR; Lu X; Winick NJ; Carroll WL; Loh ML; Hunger SP; Devidas M; Pui CH; Dolan ME; Relling MV; Evans WE
    JAMA; 2015 Feb; 313(8):815-23. PubMed ID: 25710658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of CYP3A5 Expression and Vincristine Neurotoxicity in Pediatric Malignancies in Turkish Population.
    Kayilioğlu H; Kocak U; Kan Karaer D; Percin EF; Sal E; Tekkesin F; Isik M; Oner N; Belen FB; Yilmaz Keskin E; Okur A; Albayrak M; Kaya Z; Pinarli FG; Yenicesu I; Karadeniz C; Oguz A; Gursel T
    J Pediatr Hematol Oncol; 2017 Aug; 39(6):458-462. PubMed ID: 28697165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia.
    Gutierrez-Camino Á; Umerez M; Martin-Guerrero I; García de Andoin N; Santos B; Sastre A; Echebarria-Barona A; Astigarraga I; Navajas A; Garcia-Orad A
    Pharmacogenomics J; 2018 Dec; 18(6):704-712. PubMed ID: 29282364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe Vincristine-related Neurotoxicity in 5 Patients With Pediatric Acute Lymphoblastic Leukemia Requiring Discontinuation of Vincristine: A Description of Long-term Outcome.
    Egan-Sherry D; Bhuta R; Cole PD; Gennarini LM; Kahn JM; Sulis ML; DeNardo BD; Welch JJG
    J Pediatr Hematol Oncol; 2021 Oct; 43(7):e997-e999. PubMed ID: 34001785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia.
    Stock W; Diouf B; Crews KR; Pei D; Cheng C; Laumann K; Mandrekar SJ; Luger S; Advani A; Stone RM; Larson RA; Evans WE
    Clin Pharmacol Ther; 2017 Mar; 101(3):391-395. PubMed ID: 27618250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients.
    Renbarger JL; McCammack KC; Rouse CE; Hall SD
    Pediatr Blood Cancer; 2008 Apr; 50(4):769-71. PubMed ID: 18085684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetic association with neurotoxicity in Hispanic children with acute lymphoblastic leukaemia.
    McClain CA; Bernhardt MB; Berger A; Bernini JC; Marquez-Do D; Winslow R; Scheurer ME; Schafer ES
    Br J Haematol; 2018 Jun; 181(5):684-687. PubMed ID: 28419449
    [No Abstract]   [Full Text] [Related]  

  • 11. Incidence of vincristine induced neurotoxicity in children with acute lymphoblastic leukemia and its correlation with nutritional deficiencies.
    Dudeja S; Gupta S; Sharma S; Jain A; Sharma S; Jain P; Aneja S; Chandra J
    Pediatr Hematol Oncol; 2019 Sep; 36(6):344-351. PubMed ID: 31514565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia.
    Ceppi F; Langlois-Pelletier C; Gagné V; Rousseau J; Ciolino C; De Lorenzo S; Kevin KM; Cijov D; Sallan SE; Silverman LB; Neuberg D; Kutok JL; Sinnett D; Laverdière C; Krajinovic M
    Pharmacogenomics; 2014 Jun; 15(8):1105-16. PubMed ID: 25084203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia.
    Sims RP
    J Oncol Pharm Pract; 2016 Feb; 22(1):76-81. PubMed ID: 25305360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic Variants Associated With Vincristine-Induced Peripheral Neuropathy in Two Populations of Children With Acute Lymphoblastic Leukemia.
    Li L; Sajdyk T; Smith EML; Chang CW; Li C; Ho RH; Hutchinson R; Wells E; Skiles JL; Winick N; Martin PL; Renbarger JL
    Clin Pharmacol Ther; 2019 Jun; 105(6):1421-1428. PubMed ID: 30506673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia.
    Egbelakin A; Ferguson MJ; MacGill EA; Lehmann AS; Topletz AR; Quinney SK; Li L; McCammack KC; Hall SD; Renbarger JL
    Pediatr Blood Cancer; 2011 Mar; 56(3):361-7. PubMed ID: 21225912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Pharmacogenomics of Vincristine-Induced Neuropathy: On Pins and Needles.
    Berg SL; Parsons DW
    JAMA Oncol; 2015 Oct; 1(7):975-6. PubMed ID: 26181361
    [No Abstract]   [Full Text] [Related]  

  • 17. Precision medicine to improve the risk and benefit of cancer care: genetic factors in vincristine-related neuropathy.
    McLeod HL
    JAMA; 2015 Feb; 313(8):803-4. PubMed ID: 25710656
    [No Abstract]   [Full Text] [Related]  

  • 18. Bilateral vocal cord paralysis following treatment with vincristine.
    Naithani R; Dolai TK; Kumar R
    Indian Pediatr; 2009 Jan; 46(1):68-9. PubMed ID: 19179723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluoroquinolone prophylaxis does not increase risk of neuropathy in children with acute lymphoblastic leukemia.
    Karol SE; Sun Y; Tang L; Pui CH; Ferrolino J; Allison KJ; Cross SJ; Evans WE; Crews KR; Jeha S; Wolf J
    Cancer Med; 2020 Sep; 9(18):6550-6555. PubMed ID: 32710497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach.
    Moore AS; Norris R; Price G; Nguyen T; Ni M; George R; van Breda K; Duley J; Charles B; Pinkerton R
    J Paediatr Child Health; 2011 Dec; 47(12):875-82. PubMed ID: 21658147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.